ARCHIVES

CMS also decided to cover off-label uses of approved colorectal cancer drugs in clinical trials, and allowed broader use of PET scans.

This article is from The Cancer Letter archive.

Vol. 30 No. 42 | November 5, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: Jack White Resigns As Director Of Howard Cancer Center; Roberson to Retire From Centers Program

June 1, 1984

Funding Opportunities (8-page issue).

May 23, 2003

NIH Advisors Suggest Revamping Grant Application Review

June 14, 1996

Group Lobby To Add $200 Mil. To Cancer Budget

April 26, 1991

Stand Up To Cancer Selects Five Groups For “Dream Team” Grants Totaling $73.6M.

May 29, 2009

Concurrent Trastuzumab and Anthracyclines Not Necessary for High Pathological Response

November 29, 2013